Legal & General Group
SBBP

Legal & General Group’s Strongbridge Biopharma plc. SBBP Stock Holding History

Legal & General Group’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,375
Closed -$12K – 3748
2021
Q1 		$12K Hold
4,375
– – ﹤0.01% 3340
2020
Q4 		$11K Hold
4,375
– – ﹤0.01% 3328
2020
Q3 		$9K Sell
4,375
-1,582
-27% -$5.33K ﹤0.01% 3286
2020
Q2 		$23K Buy
5,957
+2,102
+55% +$6.3K ﹤0.01% 3018
2020
Q1 		$7K Sell
3,855
-2,190
-36% -$5.69K ﹤0.01% 3231
2019
Q4 		$13K Hold
6,045
– – ﹤0.01% 3264
2019
Q3 		$14K Hold
6,045
– – ﹤0.01% 3221
2019
Q2 		$19K Buy
+6,045
New +$22.2K ﹤0.01% 3227
2018
Q2 		– Sell
-4,587
Closed -$40K – 3415
2018
Q1 		$40K Hold
4,587
– – ﹤0.01% 2862
2017
Q4 		$33K Buy
4,587
+1,406
+44% +$8.78K ﹤0.01% 3022
2017
Q3 		$22K Hold
3,181
– – ﹤0.01% 3159
2017
Q2 		$23K Buy
+3,181
New +$14.7K ﹤0.01% 3138

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Legal & General Group's SBBP Position: Q2 2021 in Review

Legal & General Group sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2021, closing a stake of 4,375 shares — an estimated $12K sold.

Legal & General Group first reported a position in SBBP in Q2 2017 and held it in 12 quarters. The position peaked at $40K in Q1 2018. 59 funds tracked by Wall St. Rank hold SBBP as of Q2 2021.

  • Legal & General Group reported no remaining Strongbridge Biopharma plc. position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 4,375 Strongbridge Biopharma plc. shares in Q2 2021, an estimated $12K.
  • Legal & General Group first reported a position in Strongbridge Biopharma plc. in Q2 2017 and held it in 12 quarters.
  • Legal & General Group's Strongbridge Biopharma plc. position peaked at $40K in Q1 2018.
  • 59 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.